NEW YORK, NY / ACCESSWIRE / November 17, 2017 / Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Acorda Therapeutics, Inc. ("Acorda" or the "Company") (NASDAQ: ACOR).
Specifically, on November 15, 2017, Acorda announced that it had identified seven cases of sepsis in patients, five of which were fatal, during the final-stage trial studies of the Company's treatment for Parkinson's disease, tozadenant. The Company also announced that new patient enrollment in the trial would be stopped.
On this news, Acorda's share price significantly declined.
If you invested in Acorda stock or options and would like to discuss your legal rights, click here: www.faruqilaw.com/ACOR. There is no cost or obligation to you.
You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com.
CONTACT:
FARUQI & FARUQI, LLP
685 Third Avenue, 26th Floor
New York, NY 10017
Attn: Richard Gonnello, Esq.
rgonnello@faruqilaw.com
Telephone: (877) 247-4292 or (212) 983-9330
Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.
SOURCE: Faruqi & Faruqi, LLP
